跳至主要内容
临床试验/NCT01435200
NCT01435200已完成3 期

Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy

Chulalongkorn University1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
64
试验地点
1
主要终点
Red blood cell (RBC) transfusion rate

研究概览

简要总结

Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?

详细描述

Anemia is a common condition during chemotherapy administration. Treatment options usually include oral iron supplementation and blood transfusion. However, oral iron has gastrointestinal side effects, which affects patient compliance, and only a small amount of oral iron can be absorbed from the gastrointestinal tract. Intravenous iron may overcome a block of iron absorption and iron recycling induced by hepcidin. Therefore, it may increase hemoglobin level and reduced blood transfusion in cancer patients receiving chemotherapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age 20-70 years
  • Good performance status (Zubrod score < 2)
  • No serious underlying disease
  • Normal renal function test
  • Normal liver function test
  • Platinum based chemotherapy is the first line regimen
  • No prior or receiving radiotherapy

排除标准

  • Iron hypersensitivity
  • Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia
  • Progressive disease
  • Bone marrow metastasis

研究组 & 干预措施

Intravenous iron

Experimental

Iron sucrose 200 mg intravenous infusion in 15 minutes

干预措施: Intravenous iron (Drug)

Oral iron

Placebo Comparator

Ferrous fumarate 200 mg oral three times a day

干预措施: Intravenous iron (Drug)

结局指标

主要结局

Red blood cell (RBC) transfusion rate

时间窗: 6 months

The requirement of red blood cell transfusion before administration of chemotherapy will be evaluated for 6 cycles of chemotherapy.

次要结局

  • Number of participants with adverse events(6 months)
  • total number of red blood transfusion units and number of cycles requiring blood transfusion(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tarinee Manchana

Department of Obstetrics and Gynecology

Chulalongkorn University

研究点 (1)

Loading locations...

相似试验

Intravenous Iron in Gynecologic Cancer Patients... | 临床试验